Product Detail
Darinaparsin-d3
Stable Isotopes
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Stable Isotopes
API Family
--
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
Darinaparsin-d3 Product Information
Darinaparsin-d3 is listed under Stable Isotopes. It is associated with and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-96983.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
Darinaparsin-d3
CAS No.
-
CAT No.
CS-T-96983
Molecular Formula
C12H19D3AsN3O6S
Molecular Weight
414.32
Category
Storage Condition
Refer MSDS for complete information.
IUPAC Name
Darinaparsin-d3
Hazard Compound
Refer MSDS for complete information.
Description
Overview
Darinaparsin-d3 is the isotope labelled analog of Darinaparsin. Darinaparsin is an arsenic cytotoxin that has been used in pharmacological activities to evaluate the effect on survival an radiosensitivity of tumor cells in vitro under normoxia and hypoxia and in vivo using xenograft models. Darinaparsin has significant and preferential cytotoxic and radiosensitizing effects on solid tumors as compared with normal cells. Darinaparsin may therefore increase the therapeutic index of radiation therapy and has near term translational potential.
Synonyms
N-[S-(Dimethylarsino)-N-L-?-glutamyl-L-cysteinyl]-glycine-d5; Dimethylarsinic Glutathione-d5; ZIO 101-d5; Zinapar-d5; L-?-Glutamyl-S-(dimethylarsino)-L-cysteinyl-glycine-d5
Application Notes
Darinaparsin-d3 is the isotope labelled analog of Darinaparsin. Darinaparsin is an arsenic cytotoxin that has been used in pharmacological activities to evaluate the effect on survival an radiosensitivity of tumor cells in vitro under normoxia and hypoxia and in vivo using xenograft models. Darinaparsin has significant and preferential cytotoxic and radiosensitizing effects on solid tumors as compared with normal cells. Darinaparsin may therefore increase the therapeutic index of radiation therapy and has near term translational potential.
References
"Tian, J., et al.: Clin. Cancer Res., 18, 3366 (2012); Ning, S., et al.: Int. J. Radiat. Oncol. Biol. Phys., 65, 493 (2006);"
